<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1722">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01686568</url>
  </required_header>
  <id_info>
    <org_study_id>12-004590</org_study_id>
    <secondary_id>KL2TR000136</secondary_id>
    <secondary_id>U24DK100469</secondary_id>
    <secondary_id>DK50456</secondary_id>
    <nct_id>NCT01686568</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids and Insulin Sensitivity</brief_title>
  <official_title>Dietary Omega-3 Fatty Acids as a Therapeutic Strategy in Insulin Resistant Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to understand the effects of dietary omega-3 fats on insulin
      sensitivity in adult men and women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dietary omega-3 polyunsaturated fatty acids (n-3 PUFA), which include eicosapentaenoic acid
      (EPA) and docosahexaenoic acid (DHA) from fish oil, prevent insulin resistance in rodents,
      but data in humans is ambiguous. No existing studies have systematically evaluated the
      influence of n-3 PUFAs on insulin sensitivity and beta cell function in insulin resistant,
      non-diabetic humans. The Investigators hypothesize that 6 months of oral supplementation of
      purified EPA/DHA (3.9g/day) will significantly improve hepatic and peripheral insulin
      sensitivity and beta cell responsiveness in insulin-resistant, non-diabetic individuals.
      Based on recent work in mice, the investigators also hypothesize that EPA/DHA will increase
      the content and function of mitochondria in skeletal muscle, measured using a combination of
      in vivo and in vitro methods. Overall, the investigators hypothesize that EPA+DHA
      supplementation will improve hepatic and peripheral insulin sensitivity in insulin resistant
      humans, and this improvement will be associated with mitochondrial biogenesis and attenuated
      lipid accumulation in skeletal muscle and liver.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp at Baseline and 6 Month Follow up</measure>
    <time_frame>Baseline, after 6 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 2-stage insulin clamp will be performed with titration of dextrose to maintain euglycemia. D2 glucose will be infused to evaluate hepatic glucose production at baseline and in response to insulin. Hyperinsulinemic-euglycemic clamp technique: The plasma insulin concentration is acutely raised and maintained by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion. When the steady-state is achieved, the glucose infusion rate (GIR) equals glucose uptake by all the tissues in the body and is therefore a measure of tissue insulin sensitivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta Cell Function From Insulin Secretion Following Ingestion of a Mixed Meal at Baseline and 6 Month Follow up</measure>
    <time_frame>baseline, after 6 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following consumption of a mixed meal, beta cell function will be evaluated from serial measurements of C-peptide. C-peptide was measured using a two-side immunometric assay using electrochemiluminescence detection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Function Determined by Muscle Biopsy at Baseline and 6 Month Follow up</measure>
    <time_frame>Baseline, after 6 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurements of oxygen consumption in isolated mitochondria will be performed using a polarographic oxygen electrode.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this group will be supplemented with placebo capsules containing ethyl oleate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.</description>
    <arm_group_label>Omega-3</arm_group_label>
    <other_name>Essential fatty acids</other_name>
    <other_name>Omega-3 fatty acids</other_name>
    <other_name>Omega-3 polyunsaturated fatty acids</other_name>
    <other_name>PUFAs</other_name>
    <other_name>Lovaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age 18-65 years

          2. Insulin resistant (Homeostasis Model Assessment (HOMA) Insulin Resistance (IR) ≥2.6)

        Exclusion criteria:

          1. Current use of omega-3 nutritional supplements

          2. Fasting plasma glucose ≥126 mg/dL

          3. Active coronary artery disease

          4. Participation in structured exercise (&gt;2 times per week for 30 minutes or longer)

          5. Smoking

          6. Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids,
             tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants)

          7. Renal failure (serum creatinine &gt; 1.5mg/dl)

          8. Chronic active liver disease (AST&gt;144 IU/L and alanine transaminase (ALT)&gt;165 IU/L)

          9. Anti-coagulant therapy (warfarin/heparin)

         10. International normalized ratio (INR) &gt;3

         11. Use of systemic glucocorticoids

         12. Chronic use of NSAIDS or aspirin

         13. Pregnancy or breastfeeding

         14. Alcohol consumption greater than 2 glasses/day

         15. Hypothyroidism

         16. Fish or shellfish allergy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Lanza, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lalia AZ, Johnson ML, Jensen MD, Hames KC, Port JD, Lanza IR. Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans. Diabetes Care. 2015 Jul;38(7):1228-37. doi: 10.2337/dc14-3101. Epub 2015 Apr 7.</citation>
    <PMID>25852206</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 16, 2015</lastchanged_date>
  <firstreceived_date>September 11, 2012</firstreceived_date>
  <firstreceived_results_date>June 16, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ian R. Lanza</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Omega-3</title>
          <description>Patients in this group will receive oral supplementation with EPA + Docosahexaenoic acid (DHA) (3.9grams/day) for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients in this group will be supplemented with placebo capsules containing ethyl oleate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Liver enzymes above range of exclusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics were reported for participants who received treatment and did not withdraw from the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Omega-3</title>
          <description>Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients in this group will be supplemented with placebo capsules containing ethyl oleate.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35.3" spread="2.9"/>
                <measurement group_id="B2" value="32.6" spread="2.5"/>
                <measurement group_id="B3" value="34.1" spread="9.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp at Baseline and 6 Month Follow up</title>
        <description>A 2-stage insulin clamp will be performed with titration of dextrose to maintain euglycemia. D2 glucose will be infused to evaluate hepatic glucose production at baseline and in response to insulin. Hyperinsulinemic-euglycemic clamp technique: The plasma insulin concentration is acutely raised and maintained by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion. When the steady-state is achieved, the glucose infusion rate (GIR) equals glucose uptake by all the tissues in the body and is therefore a measure of tissue insulin sensitivity.</description>
        <time_frame>Baseline, after 6 months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this group will be supplemented with placebo capsules containing ethyl oleate.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Insulin Sensitivity by Hyperinsulinemic-euglycemic Clamp at Baseline and 6 Month Follow up</title>
            <description>A 2-stage insulin clamp will be performed with titration of dextrose to maintain euglycemia. D2 glucose will be infused to evaluate hepatic glucose production at baseline and in response to insulin. Hyperinsulinemic-euglycemic clamp technique: The plasma insulin concentration is acutely raised and maintained by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion. When the steady-state is achieved, the glucose infusion rate (GIR) equals glucose uptake by all the tissues in the body and is therefore a measure of tissue insulin sensitivity.</description>
            <units>mg/kg FFM/min</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.92" spread="1.04"/>
                  <measurement group_id="O2" value="10.39" spread="0.76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Month Follow Up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.16" spread="1.02"/>
                  <measurement group_id="O2" value="10.80" spread="0.73"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta Cell Function From Insulin Secretion Following Ingestion of a Mixed Meal at Baseline and 6 Month Follow up</title>
        <description>Following consumption of a mixed meal, beta cell function will be evaluated from serial measurements of C-peptide. C-peptide was measured using a two-side immunometric assay using electrochemiluminescence detection.</description>
        <time_frame>baseline, after 6 months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this group will be supplemented with placebo capsules containing ethyl oleate.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Beta Cell Function From Insulin Secretion Following Ingestion of a Mixed Meal at Baseline and 6 Month Follow up</title>
            <description>Following consumption of a mixed meal, beta cell function will be evaluated from serial measurements of C-peptide. C-peptide was measured using a two-side immunometric assay using electrochemiluminescence detection.</description>
            <units>nmol/L</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="537.17" spread="45.33"/>
                  <measurement group_id="O2" value="488.90" spread="45.47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Month Follow Up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="561.33" spread="48.21"/>
                  <measurement group_id="O2" value="504.39" spread="35.93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitochondrial Function Determined by Muscle Biopsy at Baseline and 6 Month Follow up</title>
        <description>Measurements of oxygen consumption in isolated mitochondria will be performed using a polarographic oxygen electrode.</description>
        <time_frame>Baseline, after 6 months of treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this group will be supplemented with placebo capsules containing ethyl oleate.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mitochondrial Function Determined by Muscle Biopsy at Baseline and 6 Month Follow up</title>
            <description>Measurements of oxygen consumption in isolated mitochondria will be performed using a polarographic oxygen electrode.</description>
            <units>pmol/s/mg tissue</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="496.81" spread="26.54"/>
                  <measurement group_id="O2" value="564.86" spread="42.10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 Month Follow Up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="406.38" spread="40.39"/>
                  <measurement group_id="O2" value="495.12" spread="39.79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Omega-3</title>
          <description>Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients in this group will be supplemented with placebo capsules containing ethyl oleate.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ian R. Lanza</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-8147</phone>
      <email>lanza.ian@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
